PB1773: AML AND MDS WITH RARA OVEREXPRESSION: MOLECULAR AND CLINICAL FEATURES OF PATIENTS ENROLLED IN A PHASE 2 TRIAL EVALUATING TAMIBAROTENE-BASED THERAPY

• Stéphane de Botton,
• Thomas Cluzeau,
• Carlos Vigil,
• Rachel Cook,
• Philippe Rousselot,
• David Rizzieri,
• Jane Liesveld,
• Pierre Fenaux,
• Thorsten Braun,
• Arnaud Pigneux,
• Pierre Peterlin,
• Sofia Paul,
• Nisha Rajagopal,
• John Carulli,
• David Roth,
• Angela Volkert,
• Tanya Abdul Malak,
• Michael Kelly,
• Virginia Klimek,
• Eytan Stein

Affiliations

Stéphane de Botton

1 Institut Gustave Roussy, Villejuif, France

Thomas Cluzeau

2 Côte d’Azur University, CHU de Nice Hôpital, Nice, France

Carlos Vigil

3 Northwestern University, Chicago, United States

Rachel Cook

4 Oregon Health & Science University, Portland, United States

Philippe Rousselot

5 Centre Hospitalier de Versailles, Hôpital André Mignot, Le Chesnay, France

David Rizzieri

6 Duke University Medical Center

Jane Liesveld

7 University of Rochester Medical Center, Rochester, United States

Pierre Fenaux

8 Hôpital Saint Louis, Paris, France

Thorsten Braun

9 Centre Hospitalier Universitaire Hôpital Avicenne, Bobigny, France

Arnaud Pigneux

10 Hôpital Haut Leveque, Centre Francois Magendie, Bordeaux, France

Pierre Peterlin

11 Centre Hospitalier Universitaire Nantes, Nantes, France

Sofia Paul

12 Syros Pharmaceuticals, Cambridge, United States

Nisha Rajagopal

12 Syros Pharmaceuticals, Cambridge, United States

John Carulli

12 Syros Pharmaceuticals, Cambridge, United States

David Roth

12 Syros Pharmaceuticals, Cambridge, United States

Angela Volkert

12 Syros Pharmaceuticals, Cambridge, United States

Tanya Abdul Malak

12 Syros Pharmaceuticals, Cambridge, United States

Michael Kelly

12 Syros Pharmaceuticals, Cambridge, United States

Virginia Klimek

12 Syros Pharmaceuticals, Cambridge, United States

Eytan Stein

13 Memorial Sloan Kettering Cancer Center, New York, United States